The shadow of generic rivalry has long loomed above copyright’s iconic drug, Sildenafil, triggering questions about the prospects of similar medicinal holdings. While initial times saw impressive profits, the intellectual property end has created the path for discounted substitutes, possibly lowering earnings and posing a significant risk for inv